Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-307 in Moderate to Severe Ulcerative Colitis (Phase II)
CTR20180434Phase 2Completed
- Sponsor
- Concord Biotech
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of icanbelimod in autoimmune colitis, sponsored by Concord Biotech. Started Aug 2018; status: completed.
02
Drugs
icanbelimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20180434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180434.